Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$301M+44.0% YoY

Gross Profit

$77M25.6% margin

Operating Income

-$9M-3.1% margin

Net Income

-$3M-0.9% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+14.3%

Cash Flow

Operating Cash Flow

$109M

Free Cash Flow

$99M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$904M

Stockholders' Equity

$446M

Cash & Equivalents

$471M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$301M	$209M	+44.0%
Gross Profit	$77M	$129M	-40.3%
Operating Income	-$9M	$59M	-115.9%
Net Income	-$3M	$43M	-106.5%

Revenue Segments

Product

$292M33%

Radiopharmaceutical Oncology

$196M22%

PYLARIFY

$195M22%

Total Precision Diagnostics

$96M11%

DEFINITY

$69M8%

Techne Lite

$21M2%

Strategic Partnerships And Other

$9M1%

License and Royalty Revenues

$9M1%

Other Precision Diagnostics

$6M1%

Other Radiopharmaceutical Oncology

$717,0000%